Skip to main content
. 2021 Oct 15;11:16866. doi: 10.1038/s41598-021-96351-2

Figure 5.

Figure 5

In vivo distribution of lapatinib-loaded hiPSC-platelets. (A) Body weights of variously treated BBM1-derived tumor-bearing female NOD/SCID mice (n = 7) over a 30-day period. ** indicates p < 0.001. (B) Plasma concentrations of lapatinib, measured by LC–MS/MS after injection with free lapatinib or lapatinib-loaded hiPSC- and donor-derived platelets in NOD/SCID mice (n = 7). Lapatinib-loaded hiPSC- and donor-derived platelets vs. free lapatinib, * p < 0.001. (C) Lapatinib concentrations in various tissues of female NOD/SCID mice (n = 7), collected 4 h after infusion with free lapatinib or lapatinib-loaded hiPSC- and donor-derived platelets. * indicates p < 0.001.